- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
Lupin received U.S. FDA final approval for its generic Pitolisant Tablets (4.45 mg & 17.8 mg), bioequivalent to Wakix®. This expands the company's product portfolio for the US market.